- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Sarecycline approved for moderate-to-severe acne
The Food and Drug Administration (FDA) approved sarecycline (Seysara, Almirall, S.A.) in October for the treatment of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older, according to a company news release.
Sarecycline (Seysara, Almirall, S.A.) has been approved for the treatment of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. (OcskayBence - stock.adobe.com)
The Food and Drug Administration (FDA) approved sarecycline (Seysara, Almirall, S.A.) in October for the treatment of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older, according to a company news release.
Sarecycline is a first in class tetracycline-derived once-daily oral antibiotic. The approval was based on data from two 12-week multicenter, randomized, double-blind, placebo-controlled efficacy studies. Researchers enrolled 2,002 patients aged 9 years and older and the drug was found to significantly reduced inflammatory lesions as early as 3 weeks after treatment, the company says.
Sarecycline was part of Allergan’s Medical Dermatology portfolio. It was recently acquired by Almirall for the United States and is expected to be launched in January 2019.
